Navigation Links
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Date:1/6/2009

Program Expands on Successful Results from prior U.S., U.K. and China Trials

SAN DIEGO, Jan. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, today announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.

This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.

ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.

For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.

VTI Chairman and CE
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
2. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
3. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... VANCOUVER, Jan. 30 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... its modified "Dutch Auction" tender offer (the "Offer"), which expired ... QLT has accepted for purchase and cancellation 20,000,000 of its ... Share, for a total cost of US$50 million. The purchased ...
... (Nasdaq: LCAV ), a leading provider of laser ... announced that it will release fourth quarter and full year ... 10, 2009. A conference call and webcast to discuss ... 2009 at 10:00 a.m. Eastern time.To access the conference call, ...
... CEO of America,s Health Insurance Plans (AHIP), today issued ... to reauthorize and expand the State Children,s Health Insurance ... is an essential component of comprehensive health care reform. ... by voting to help ensure that no child falls ...
... classified by the government as overweight, and with ... even more difficult for people to lose weight, ... MD from Russia ( www.drolga.com ) offers clients ... on CD at www.drolga.com and through ...
... certification allows pharmacies using the Company,s POS product to comply with ... , ... Fountain Valley, CA (PRWEB) January 30, 2009-- ... of Sale software has received SIGIS (Special Interest Group - IIAS ...
... division of HCPro, Inc., announced today the ... website that provides the pharmaceutical and medical ... educate staff and maintain compliance with government ... training products offered by ePharmaceuticals™ into one ...
Cached Medicine News:Health News:QLT announces final results of tender offer 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 3Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 2Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 2Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: